Castle Biosciences Honored with Top Workplaces Awards
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle honored as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards.
- 07/11/2024
|
Top 5 Health Care Stocks That May Explode In July
- The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
- 07/08/2024
|
Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences' TissueCypher® Test
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AGA--The latest AGA clinical practice guideline acknowledges the role that TissueCypher can play identifying high-risk Barrett's esophagus patients.
- 06/24/2024
|
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
- We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.
- 06/21/2024
|
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4).
- 06/20/2024
|
Castle Biosciences' Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's founder, president & CEO, Derek Maetzold, has been named an EY 2024 Entrepreneur Of The Year® for the Gulf South region.
- 06/14/2024
|
Is Castle Biosciences (CSTL) Outperforming Other Medical Stocks This Year?
- Here is how Castle Biosciences, Inc. (CSTL) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
- 06/13/2024
|
Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASCO--Castle will present new data related to its DecisionDx-Melanoma and DecisionDx-UM tests at the 2024 ASCO Annual Meeting, May 31-June 4, 2024.
- 05/30/2024
|
New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced the publication of a study demonstrating the impact of the DecisionDx-SCC test in guiding adjuvant radiation therapy decision-making.
- 05/29/2024
|
Does Castle Biosciences (CSTL) Have the Potential to Rally 36.15% as Wall Street Analysts Expect?
- The average of price targets set by Wall Street analysts indicates a potential upside of 36.2% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 05/23/2024
|
What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing'
- Castle Biosciences (CSTL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
- 05/23/2024
|
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle executive management is scheduled to present a company overview at the Leerink Partners Healthcare Crossroads Conference May 29 at 2pm ET.
- 05/15/2024
|
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett's Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Barrettsesophagus--Castle will share three abstracts related to its TissueCypher® test at DDW 2024.
- 05/14/2024
|
Castle Biosciences' IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle awarded the “Best Overall Mental Health Solution” in 8th annual MedTech Breakthrough Awards program for IDgenetix® pharmacogenomic (PGx) test.
- 05/10/2024
|
Wall Street Analysts Predict a 36.09% Upside in Castle Biosciences (CSTL): Here's What You Should Know
- The mean of analysts' price targets for Castle Biosciences (CSTL) points to a 36.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 05/07/2024
|
Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable
- Castle Biosciences (CSTL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
- 05/06/2024
|
Castle Biosciences, Inc. (CSTL) Q1 2024 Earnings Call Transcript
- Castle Biosciences, Inc. (NASDAQ:CSTL ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR & Corporate Affairs Derek Maetzold - President, CEO, Founder & Director Frank Stokes - CFO Conference Call Participants Subbu Nambi - Guggenheim Kyle Mikson - Canaccord Genuity Corey Rosenbaum - Scotiabank Thomas Flaten - Lake Street Paul Knight - KeyBanc Mason Carrico - Stephens Catherine Schulte - Baird Operator Good afternoon, and welcome to Castle Biosciences First Quarter 2024 Conference Call. As a remainder, today's call is being recorded.
- 05/04/2024
|
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ACMS--Castle Biosciences will share new data supporting the utility of its DecisionDx®-SCC test at the ACMS Annual Meeting in Phoenix.
- 05/03/2024
|
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
- Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $1.10 per share a year ago.
- 05/02/2024
|
Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood's Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences announced its support of key skin cancer advocacy events and initiatives throughout May in honor of Skin Cancer Awareness Month.
- 04/30/2024
|
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release its financial results for the first quarter ended March 31, 2024, after the close of market on Thursday, May 2, 2024.
- 04/11/2024
|
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle recognizes the importance of Esophageal Cancer Awareness Month and is providing its support of key programs and initiatives throughout April.
- 04/10/2024
|
Castle Biosciences' Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--For the second year in a row, Castle's chief financial officer, Frank Stokes, has been selected as a Top 25 CFO of Houston by TOP CFOs.
- 04/10/2024
|
Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will share new data on its DecisionDx-Melanoma and DecisionDx-SCC tests at the 20th European Association of Dermato-Oncology (EADO) Congress.
- 04/04/2024
|
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's executive management will present a company overview at the 23rd Annual Needham Virtual Healthcare Conference Tuesday, 4/9/24 at 12:45pm ET.
- 04/02/2024
|
Castle Biosciences Announces Updates to its Board of Directors
- FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle today announced that Rodney Cotton has been appointed to its board of directors, effective immediately.
- 03/27/2024
|
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announced it has received a Top Workplaces USA award for the third consecutive year.
- 03/25/2024
|
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced new data highlighting the performance of its DecisionDx-Melanoma test in predicting risk of SLN positivity in patients with melanoma.
- 03/22/2024
|
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #40GEP--Expert consensus article in JCAD recommends framework including DecisionDx-SCC test for adjuvant radiation therapy decision-making in SCC patients.
- 03/19/2024
|
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences' IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announces new data highlighting its IDgenetix PGx test in guiding medication recommendations for patients 65+ with mental health conditions.
- 03/15/2024
|
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management will present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum.
- 03/12/2024
|
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AAD2024--Castle Biosciences announces it will share data across its dermatologic portfolio of gene expression profile tests at the 2024 AAD Annual Meeting.
- 03/08/2024
|
Castle Biosciences, Inc. (CSTL) Q4 2023 Earnings Call Transcript
- Castle Biosciences, Inc. (CSTL) Q4 2023 Earnings Call Transcript
- 02/28/2024
|
Castle Biosciences, Inc. (CSTL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
- The headline numbers for Castle Biosciences, Inc. (CSTL) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 02/28/2024
|
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
- Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.78 per share a year ago.
- 02/28/2024
|
Castle Biosciences to Present at Upcoming Investor Conferences
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management will present a company overview at three investor conferences later this month.
- 11/08/2023
|
Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q3 Earnings
- Although the revenue and EPS for Castle Biosciences, Inc. (CSTL) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 11/02/2023
|
Castle Biosciences to Participate in Upcoming Investor Conferences
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences today announced that Derek Maetzold and Frank Stokes will present a company overview at Baird's 2023 Global Healthcare Conference.
- 09/05/2023
|
Why Castle Biosciences Stock Is Jumping Today
- Castle reported stronger Q2 revenue growth and a lower net loss than analysts anticipated. The company also raised its full-year revenue outlook.
- 08/03/2023
|
Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q2 Earnings
- While the top- and bottom-line numbers for Castle Biosciences, Inc. (CSTL) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 08/02/2023
|
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline
- Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/26/2023
|
Castle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the second quarter and six months ended June 30, 2023, after the close of market on Aug. 2, 2023.
- 07/19/2023
|
Why Shares of Castle Biosciences Fell This Week
- Castle's CEO and board chairman each unloaded significant amounts of company stock. The company focuses on medical diagnostic tests, primarily to inform cancer treatment choices.
- 07/13/2023
|
Castle Biosciences stock soars on Medicare reversal; data presentation
- Castle Biosciences, Inc shares surged 55% to $20.64 on Friday after Novitas, a regional Medicare administrative contractor, reversed its draft policy that would have denied coverage of Castle's DecisionDx cancer tests for squamous cell carcinoma (SCC) and melanoma. Novitas stated that its original local coverage determination (LCD) was scheduled to go into effect on July 17, 2023, and now plans to create a new draft LCD for Castle's DecisionDx tests.
- 07/07/2023
|
Why Castle Biosciences Stock Is Crushing It Today
- Novitas is withdrawing a draft policy that would have denied coverage for Castle's cancer tests. It must still wait on a new draft policy from the regional Medicare administrative contractor.
- 07/07/2023
|
Castle Biosciences to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at the American Head & Neck Society's (AHNS) 11th International Conference on Head and Neck Cancer
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present new data on DecisionDx®-SCC and DecisionDx®-Melanoma at AHNS' 11th International Conference on Head and Neck Cancer.
- 07/07/2023
|
Why Shares of Castle Biosciences Plummeted on Monday
- A Medicare contractor proposed non-coverage of one of Castle's skin cancer tests. The company reiterated guidance.
- 06/05/2023
|
Why Shares of Castle Biosciences Slumped This Week
- Castle Biosciences' shares are down more than 3% this year. The company specializes in medical diagnostics to improve patient treatment plans.
- 06/02/2023
|
Castle Biosciences, Inc. (CSTL) Q1 2023 Earnings Call Transcript
- Castle Biosciences, Inc. (NASDAQ:CSTL ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations & Corporate Affairs Derek Maetzold - Founder, President & Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Puneet Souda - SVB Catherine Schulte - Baird Mark Massaro - BTIG Sung Ji Nam - Scotiabank Operator Good afternoon, and welcome to Castle Biosciences First Quarter 2023 Conference Call. As a reminder, today's call is being recorded.
- 05/03/2023
|
7 Value Stocks to Buy for Long-Term Growth
- For investors that have the patience to ride out volatility in exchange for possible long-term upside, value stocks to buy that are discounted against book value may offer considerable intrigue. On paper, book value represents the difference between the company's total assets and total liabilities.
- 03/26/2023
|
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on March 22 at 2:15 p.m. Eastern.
- 03/14/2023
|
Castle Biosciences, Inc. (CSTL) Q4 2022 Earnings Call Transcript
- Castle Biosciences, Inc. (NASDAQ:CSTL ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs Derek Maetzold - Founder, President and Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Thomas Flaten - Lake Street Operator Good afternoon, and welcome to Castle Biosciences Fourth Quarter 2022 Conference Call. As a reminder, today's call is being recorded.
- 03/03/2023
|
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
- Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 14.29% and 4.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/28/2023
|
Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the fourth quarter and year ended Dec. 31, 2022, after the close of market on Tuesday, Feb. 28, 2023.
- 02/07/2023
|
Castle Biosciences: Potential To Re-Rate With Supportive Fundamentals, Technicals, Underlying Market
- Castle Biosciences has niche exposure to skin cancer, offering uncorrelated alpha potential. The stock is beaten down, with a chance to re-rate to the upside.
- 12/15/2022
|
Castle Biosciences, Inc. (CSTL) Q3 2022 Earnings Call Transcript
- Castle Biosciences, Inc. (NASDAQ:CSTL ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs Derek Maetzold - Founder, President and Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Catherine Schulte - Baird Puneet Souda - SVB Securities Thomas Flaten - Lake Street Mark Massaro - BTIG Mason Carrico - Stephens, Inc Operator Good afternoon and welcome to Castle Biosciences Third Quarter 2022 Conference Call. [Operator Instructions] I would like to turn the call over to Camilla Zuckero, Vice President, Investor Relations and Corporate Affairs.
- 11/03/2022
|
Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced new data showing that DecisionDx-SCC test results positively impacted patient management in over 80% of a Medicare-eligible cohort.
- 10/24/2022
|
Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present data highlighting its portfolio of skin cancer GEP tests at the 2022 ASDS Annual Meeting.
- 10/10/2022
|
Castle Biosciences to Participate in Upcoming Investor Conferences
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences is scheduled to present a company overview at Baird's 2022 Global Healthcare Conference on Tuesday, Sept. 13, 2022, at 2 p.m. ET.
- 09/01/2022
|
Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q2 2022 Results - Earnings Call Transcript
- Castle Biosciences, Inc. (NASDAQ:CSTL ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Camilla Zuckero - Executive Director of IR & Corporate Communications Derek Maetzold - Founder, President & CEO Frank Stokes - CFO Conference Call Participants Mason Carrico - Stephens Tom Peterson - Baird Puneet Souda - SVB Leerink Operator Good afternoon, and welcome to the Castle Biosciences Second Quarter 2022 Conference Call. As a reminder, today's call is being recorded.
- 08/12/2022
|
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
- Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 89.66% and 22.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/08/2022
|
Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth Conference
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present a company overview at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, Aug. 10, 2022, at 1:00 p.m. Eastern time
- 08/03/2022
|
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline
- Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/01/2022
|
Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the second quarter and six months ended June 30, 2022, on Monday, Aug. 8, 2022.
- 07/25/2022
|
7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years
- Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF.
- 05/11/2022
|
Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q1 2022 Results - Earnings Call Transcript
- Castle Biosciences, Inc. (NASDAQ:CSTL ) Q1 2022 Results Conference Call May 9, 2022 4:30 PM ET Company Participants Camilla Zuckero - Executive Director of Investor Relations and Corporate Communications Derek Maetzold - Founder, President and Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Leerink Catherine Schulte - Baird Mason Carrico - Stephens Thomas Flaten - Lake Street Capital Markets Kyle Mikson - Canaccord Mark Massaro - BTIG Operator Good afternoon, and welcome to Castle Biosciences First Quarter 2022 Conference Call. As a reminder, today's call is being recorded.
- 05/09/2022
|
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
- Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -19.40% and 6.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/09/2022
|
Castle Biosciences to Release First Quarter 2022 Financial Results and Host Conference Call on Monday, May 9
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences will release its financial results for the first quarter ended March 31, 2022, after the close of market on Monday, May 9, 2022.
- 04/25/2022
|
Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present data on its skin cancer gene expression profile tests at the 18th European Association of Dermato Oncology (EADO) Congress.
- 04/20/2022
|
Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences will present a company overview at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 3:00 p.m. ET.
- 04/05/2022
|
Castle Biosciences, Inc.'s (CSTL) CEO Derek Maetzold on Q4 2021 Results - Earnings Call Transcript
- Castle Biosciences, Inc.'s (CSTL) CEO Derek Maetzold on Q4 2021 Results - Earnings Call Transcript
- 02/28/2022
|
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
- Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 41.86% and 6.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/28/2022
|
Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the fourth quarter and year-ended Dec. 31, 2021, after the close of market on Monday, Feb. 28, 2022.
- 02/14/2022
|
Castle Biosciences to Present at the 24th Annual Needham Growth Conference
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences is scheduled to present a company overview at the 24th Annual Needham Growth Conference, Jan. 10, 2022, at 12:30 p.m. Eastern time.
- 12/28/2021
|
What's Next For Castle Biosciences Stock?
- The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to its downbeat Q3 results.
- 11/11/2021
|
Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q3 2021 Results - Earnings Call Transcript
- Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q3 2021 Results - Earnings Call Transcript
- 11/08/2021
|
Castle Biosciences to Release Third Quarter 2021 Financial Results and Host Conference Call on Monday, Nov. 8, 2021
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle will release its financial results for the third quarter and nine months ended Sept. 30, 2021, after the close of market on Nov. 8, 2021.
- 10/25/2021
|
Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced that it has been awarded a five-year U.S. Federal Supply Schedule (FSS) contract for its DecisionDx®-Melanoma test.
- 08/24/2021
|
Castle Biosciences, Inc (CSTL) CEO Derek Maetzold on Q2 2021 Results - Earnings Call Transcript
- Castle Biosciences, Inc (CSTL) CEO Derek Maetzold on Q2 2021 Results - Earnings Call Transcript
- 08/11/2021
|
Castle Biosciences Q2 Earnings Edges Out Expectation On Record Test Report Volume
- After the market close on Monday, Castle Biosciences Inc (NASDAQ: CSTL) reported that its second-quarter revenues rose 79% Y/Y to $22.75 million, beating the consensus of $18.93 million. The increase was attributable to more than double the number of tests delivered during the quarter.
- 08/10/2021
|
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
- Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -17.24% and 19.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/09/2021
|
Castle Biosciences to Present Data at the 2021 American Academy of Dermatology (AAD) Summer Meeting
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences announced oral data presentations on two of its skin cancer gene expression profile tests during the 2021 AAD Summer Meeting.
- 08/06/2021
|
Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for
- Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/02/2021
|
Castle Biosciences Collaborates with the Melanoma Research Foundation
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle today announced its continued collaboration with the Melanoma Research Foundation (MRF).
- 08/02/2021
|
Castle Biosciences to Release Second Quarter 2021 Financial Results and Host Conference Call on Monday, Aug. 9, 2021
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences announced that it will release its financial results for the second quarter and six months ended June 30, 2021 on Aug. 9, 2021.
- 07/26/2021
|
Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx®-SCC at SDPA Annual Summer Dermatology Conference 2021
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #SDPA--Castle Biosciences announced data presentations at the Society of Dermatology Physician Assistants (SDPA) Annual Summer Dermatology Conference 2021.
- 07/22/2021
|
Castle Biosciences Expands its Board of Directors with New Appointments
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #boardofdirectors--Castle announced that Kim Caple and Ellen Goldberg have been appointed to its board of directors, effective immediately.
- 07/16/2021
|
AltheaDx, Inc. appoints industry veteran Derek Maetzold to its Board of Directors
- SAN DIEGO, May 26, 2021 /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has appointed Derek Maetzold to its Board of Directors. Mr. Maetzold is AltheaDx's fourth Director and brings not only strong knowledge of the diagnostics industry, but also operations and management experience.
- 05/26/2021
|
Castle Biosciences Supports the American Skin Association with Research Grant
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AmericanSkinAssociation--Castle today announced its collaboration with the American Skin Association to provide a 2021 research grant in the area of melanoma.
- 05/21/2021
|
Castle Biosciences, Inc (CSTL) CEO Derek Maetzold on Q1 2021 Results - Earnings Call Transcript
- Castle Biosciences, Inc (CSTL) CEO Derek Maetzold on Q1 2021 Results - Earnings Call Transcript
- 05/10/2021
|
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
- Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 22.73% and 33.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/10/2021
|
Castle Biosciences: Q1 Earnings Insights
- Shares of Castle Biosciences (NASDAQ:CSTL) were unchanged in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 666.67% over the past year to ($0.17), which beat the estimate of ($0.24).
- 05/10/2021
|
Castle Biosciences Announces First Quarter 2021 Results
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle today announced its financial results for the first quarter ended March 31, 2021.
- 05/10/2021
|
Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for
- Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/03/2021
|
Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DiffDxMelanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced it has signed a definitive agreement to acquire all of the equity of Myriad myPath, LLC (Myriad myPath Laboratory), from Myriad Genetics. Myriad myPath Laboratory is a CLIA-certified laboratory in Salt Lake City, where the myPath Melanoma 23-gene expression profile (GEP) test was develope
- 04/27/2021
|
Castle Biosciences Presents Data at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology Congress
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #10thWCM--Castle presented data on its three skin cancer gene expression profile tests at the 10th World Congress of Melanoma.
- 04/16/2021
|
Castle Biosciences Announces Prospective, Multi-Center Publication Demonstrating DecisionDx®-Melanoma as Significant, Independent Predictor of Patient Outcomes in Cutaneous Melanoma
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Melanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of prospective, multi-center long-term outcomes data in cutaneous melanoma as impacted by DecisionDx®-Melanoma. DecisionDx-Melanoma is Castle's gene expression profile test that uses an individual patient's tumor biology to predict risk of cutaneous melanoma metastasis or
- 04/13/2021
|
Castle Biosciences Collaborates with the Melanoma Research Foundation for “Ask the Expert” Live Webinar Series with Melanoma Experts
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announced it will collaborate with the Melanoma Research Foundation (MRF) to present “Ask the Expert” Managing Melanoma, a webinar series.
- 04/01/2021
|
Castle Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 4:30 p.m. Eastern time. A live audio webcast of the company's presentation will be available by visiting Ca
- 03/29/2021
|
Castle Biosciences Announces Publication Demonstrating Dermatologists Are Increasingly Integrating DecisionDx-Melanoma Into Melanoma Clinical Management Decisions
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of a cross-sectional study of dermatologists that found its respondents are increasingly incorporating DecisionDx®-Melanoma into the management of their patients with melanoma. DecisionDx-Melanoma is Castle's gene expression profile test that uses an individual patient's t
- 03/25/2021
|
Can Castle Biosciences Stock Rebound After The Recent 24% Drop?
- The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days. We believe the stock, after the recent drop, may trend higher in the near term.
- 03/12/2021
|
Castle Biosciences, Inc. (CSTL) Moves 5.3% Higher: Will This Strength Last?
- Castle Biosciences, Inc. (CSTL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 03/11/2021
|
Castle Biosciences, Inc (CSTL) CEO Derek Maetzold on Q4 2020 Results - Earnings Call Transcript
- Castle Biosciences, Inc (CSTL) CEO Derek Maetzold on Q4 2020 Results - Earnings Call Transcript
- 03/08/2021
|
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
- Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -45.45% and 10.62%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/08/2021
|
Castle Biosciences Announces Fourth Quarter and Full-Year 2020 Results
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences Announces Fourth Quarter and Full-Year 2020 Results
- 03/08/2021
|
Is a Surprise Coming for Castle Biosciences (CSTL) This Earnings Season?
- Castle Biosciences (CSTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 03/05/2021
|
Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Castle Biosciences, Inc. (CSTL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 03/01/2021
|
Castle Biosciences to Release Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Monday, March 8, 2021
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #SkinCancer--Castle will release its financial results for the fourth quarter and year-ended December 31, 2020, after the close of market on Monday, March 8, 2021.
- 02/22/2021
|
Castle Biosciences to Present at Upcoming Investor Conferences
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences is scheduled to present a company overview at upcoming investor conferences.
- 02/08/2021
|
Castle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19th Annual South Beach Symposium
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle today announced virtual posters on its three skin cancer gene expression profile tests at the 19th Annual South Beach Symposium.
- 02/04/2021
|
Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference.
- 01/20/2021
|
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2020 Results
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Castle--Castle today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2020.
- 01/13/2021
|
Castle Biosciences to Present at the 23rd Annual Needham Virtual Growth Conference
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle is scheduled to present a company overview at the 23rd Annual Needham Virtual Growth Conference on Jan. 15, 2021.
- 01/04/2021
|
Castle Biosciences Announces Early Repayment of Debt
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #skincancer--Castle today announced it prepaid in full its outstanding term loan facility.
- 12/22/2020
|
Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences today announced the closing of its previously announced underwritten public offering.
- 12/18/2020
|
Castle Biosciences Announces Pricing of $232 Million Public Offering of Common Stock
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences announced today the pricing of its underwritten public offering.
- 12/15/2020
|
Castle Biosciences Announces Commencement of Proposed Public Offering of Common Stock
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle announced today that it has commenced a proposed underwritten public offering.
- 12/14/2020
|
Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences Announces Publication of Peer-Reviewed Publication Demonstrating the Clinical Impact of DecisionDx®-Melanoma
- 12/04/2020
|
Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #cancerdiagnostics--Castle Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
- 11/23/2020
|
Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx® DiffDx™-Melanoma for Suspicious Pigmented Lesions
- FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences Announces Publication of Clinical Validation and Utility Data for DecisionDx® DiffDx™-Melanoma for Suspicious Pigmented Lesions.
- 11/17/2020
|
Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q3 2020 Results - Earnings Call Transcript
- Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q3 2020 Results - Earnings Call Transcript
- 11/09/2020
|
Melanoma Research Alliance Announces 13 Dermatology Fellowship Awards
- The Melanoma Research Alliance, the largest non-profit funder of melanoma research, has named 13 promising clinicians/researchers-in-training as 2020
- 10/08/2020
|
Melanoma Therapeutics Market Size, Analysis Top Countries In-depth Research, Trends, Emerging Growth Factors and Regional Forecasts to 2026
- Oct 01, 2020 (The Expresswire) --
“Melanoma Therapeutics Market" report provides a detailed evaluation of the market by highlighting information on different...
- 10/01/2020
|
Melanoma Therapeutics Market 2020 Share, Size, Regional Trend, Future Growth, Leading Players Updates, Industry Demand, Current and Future Plans by Forecast to 2026
- Oct 01, 2020 (The Expresswire) --
Global "Melanoma Therapeutics Market" 2020 report includes the market strategy, market orientation, expertise opinion and...
- 10/01/2020
|
Melanoma Therapeutics Market 2020 Share, Size, Regional Trend, Future Growth, Leading Players Updates, Industry Demand, Current and Future Plans by Forecast to 2026
- Oct 01, 2020 (The Expresswire) --
Global "Melanoma Therapeutics Market" 2020 report includes the market strategy, market orientation, expertise opinion and...
- 10/01/2020
|
Melanoma Therapeutics Market 2020 Share, Size, Regional Trend, Future Growth, Leading Players Updates, Industry Demand, Current and Future Plans by Forecast to 2026
- Oct 01, 2020 (The Expresswire) --
Global "Melanoma Therapeutics Market" 2020 report includes the market strategy, market orientation, expertise opinion and...
- 10/01/2020
|
TriSalus Life Sciences Lays Out Therapeutic Strategy Upon Acquisition of First Therapeutic Candidate
- TriSalus Life Sciences announces its therapeutic clinical development strategy following the acquisition of SD-101, from Dynavax Technologies.
- 09/24/2020
|
Europe Melanoma Market and Competitive Landscape Report 2020: Pipeline, Epidemiology, Market Valuations, Drug Sales, Market Forecast, Drug Forecasts, & Market Shares 2016-2024 - ResearchAndMarkets.com
|
Apple App Store Approves Everbridge’s Next-Gen COVID-19 Contact Tracing Software Solution Amid Continued Global Adoption By Education, Retail, Hospital and Government Sectors
- Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced approval for the latest version of its next-gen
- 09/14/2020
|
Daniel Bradbury Sells 3,750 Shares of Castle Biosciences (NASDAQ:CSTL) Stock
- Castle Biosciences (NASDAQ:CSTL) Director Daniel Bradbury sold 3,750 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $43.18, for a total value of $161,925.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC […]
- 08/22/2020
|
The Daily Biotech Pulse: CureVac Close To Coronavirus Vaccine Deal With EU, Entera Bio's Positive Readout, Patent Protection For Co-Diagnostics
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
10X Genomics Inc (NASDAQ: TXG)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Avenue Therapeutics Inc (NASDAQ: ATXI)...
- 08/20/2020
|
A Closer Look At Castle Biosciences, Inc.'s (NASDAQ:CSTL) Uninspiring ROE
- Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- 08/11/2020
|
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
- Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 80.95% and 39.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/10/2020
|
Castle Biosciences Announces Second Quarter 2020 Results
- Castle Biosciences today announced its financial results for the second quarter and six months ended June 30, 2020.
- 08/10/2020
|
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
- Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
- 08/09/2020
|
Castle Biosciences to Present at the Canaccord Genuity 40th Annual Growth Conference
- Castle Biosciences is scheduled to present a company overview at the Canaccord Genuity 40th Annual Growth Conference on Wednesday, August 12, 2020.
- 08/05/2020
|
Castle Biosciences, Inc. (CSTL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/03/2020
|
Castle Biosciences (NASDAQ:CSTL) Expected to Announce Earnings of -$0.42 Per Share
- Wall Street brokerages forecast that Castle Biosciences (NASDAQ:CSTL) will report earnings per share of ($0.42) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Castle Biosciences’ earnings. The highest EPS estimate is ($0.35) and the lowest is ($0.48). Castle Biosciences posted earnings per share of ($1.05) in the same […]
- 08/03/2020
|
Castle Biosciences to Release Second Quarter 2020 Financial Results and Host Conference Call on Monday, August 10, 2020
- Castle will release its financial results for the second quarter ended June 30, 2020, after the close of market on Monday, August 10, 2020.
- 07/27/2020
|
Castle Biosciences to Release Second Quarter 2020 Financial Results and Host Conference Call on Monday, August 10, 2020
- Castle will release its financial results for the second quarter ended June 30, 2020, after the close of market on Monday, August 10, 2020.
- 07/27/2020
|
Castle Biosciences (NASDAQ:CSTL) Reaches New 12-Month High at $45.27
- Shares of Castle Biosciences (NASDAQ:CSTL) hit a new 52-week high during trading on Wednesday . The stock traded as high as $45.27 and last traded at $44.28, with a volume of 38331 shares changing hands. The stock had previously closed at $42.97. Several equities research analysts have recently issued reports on CSTL shares. Zacks Investment […]
- 07/17/2020
|
The Daily Biotech Pulse: 2 IPOs, Nabriva Pneumonia Drug Gets Canadian Regulatory Nod, PhaseBio Doses First COVID-19 Trial Patient
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 16)
AC Immune SA (NASDAQ: ACIU...
- 07/17/2020
|
Castle Biosciences Announces Publication of Clinical Utility, Long-Term Outcomes Data and Meta-Analysis for DecisionDx-UM for Patients with Uveal Melanoma
- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of a multicenter, prospective study demonstrating that DecisionDx®-UM test results significantly impacted treatment plan recommendations for patients with uveal melanoma (UM).
- 07/15/2020
|
Castle Biosciences Announces Publication of Clinical Utility, Long-Term Outcomes Data and Meta-Analysis for DecisionDx-UM for Patients with Uveal Melanoma
- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment deci
- 07/15/2020
|
Head to Head Analysis: Cancer Genetics (NASDAQ:CGIX) and Castle Biosciences (NASDAQ:CSTL)
- Cancer Genetics (NASDAQ:CGIX) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership. Analyst Ratings This is a breakdown of current recommendations for Cancer Genetics and Castle Biosciences, […]
- 07/14/2020
|
Second Systematic Review and Meta-Analysis Published Demonstrating DecisionDx-Melanoma as Independent Predictor of Recurrence, Distant Metastasis and Overall Survival in Cutaneous Melanoma
- Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of an independent, systematic review and meta-analysis demonstrating that its DecisionDx®-Melanoma test is a significant predictor of recurrence and metastatic risk in patients with invasive cutaneous melanoma.
- 07/09/2020
|
What Type Of Shareholders Own The Most Number of Castle Biosciences, Inc. (NASDAQ:CSTL) Shares?
- A look at the shareholders of Castle Biosciences, Inc. (NASDAQ:CSTL) can tell us which group is most powerful...
- 07/06/2020
|
Castle Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock
- Castle announced the underwriters have exercised in full their option to purchase an additional 300,000 shares.
- 07/02/2020
|
Guardant Health (GH) Receives a Buy from Canaccord Genuity - Markets
- In a report released today, Max Masucci from Canaccord Genuity maintained a Buy rating on Guardant Health (GH – Research
- 07/02/2020
|
Castle Biosciences Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock
- Castle announced the underwriters have exercised in full their option to purchase an additional 300,000 shares.
- 07/02/2020
|
'My husband died from a cancer that is preventable'
- Cliona Murphy lost her husband Brendan to melanoma three years ago. Here, she talks about the difference new treatments made to extending his life, as well as the need for fundraising to continue research into further treatments.
- 07/01/2020
|
Hedge Funds Are Betting On Castle Biosciences, Inc. (CSTL)
- In this article we will check out the progression of hedge fund sentiment towards Castle Biosciences, Inc. (NASDAQ:CSTL) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]
- 06/26/2020
|
Castle Biosciences Announces Pricing of $74.0 Million Public Offering of Common Stock
- Castle Biosciences announced today the pricing of its underwritten public offering.
- 06/25/2020
|
Castle Biosciences Announces Pricing of $74.0 Million Public Offering of Common Stock
- Castle Biosciences announced today the pricing of its underwritten public offering.
- 06/25/2020
|
The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout
- The following is a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 22)
ADC Therapeutics SA (...
- 06/23/2020
|
Castle Biosciences Announces Proposed Underwritten Public Offering of Common Stock
|
Castle Biosciences Announces Proposed Underwritten Public Offering of Common Stock
- Castle Biosciences has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC).
- 06/22/2020
|
Castle Biosciences Announces Proposed Underwritten Public Offering of Common Stock
- Castle Biosciences has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC).
- 06/22/2020
|
The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 18)
ADC Therapeutics SA (NYSE:...
- 06/19/2020
|
The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 16)
Applied Molecular Transport...
- 06/16/2020
|
Joseph C. Cook III Sells 2,108 Shares of Castle Biosciences (NASDAQ:CSTL) Stock
- Castle Biosciences (NASDAQ:CSTL) Director Joseph C. Cook III sold 2,108 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $39.00, for a total value of $82,212.00. Following the completion of the sale, the director now directly owns 212,178 shares of the company’s stock, […]
- 06/14/2020
|
Castle Biosciences (NASDAQ:CSTL) and Anpac Bio-Medical Science (NASDAQ:ANPC) Head-To-Head Survey
- Castle Biosciences (NASDAQ:CSTL) and Anpac Bio-Medical Science (NASDAQ:ANPC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability. Insider and Institutional Ownership 42.7% of Castle Biosciences shares are owned by institutional investors. […]
- 06/14/2020
|
GenMark (GNMK) Receives a Buy from Canaccord Genuity - Markets
- Canaccord Genuity analyst Max Masucci maintained a Buy rating on GenMark (GNMK – Research Report) yesterday and set a price
- 06/11/2020
|
Skin cancer symptoms: The sign in your feet that could signal the deadly disease
- SKIN cancer symptoms most often develop on areas of the skin that have been exposed to the sun, but it can also develop on less obvious areas such as the feet. One sign of melanoma skin cancer - one of the more serious types of skin cancer - can appear on a person's toenails.
- 06/01/2020
|
Castle Biosciences Announces Change of Location of Annual Meeting of Stockholders to Be Held June 4, 2020
- Castle announced a change of location of its 2020 Annual Meeting of Stockholders to The San Luis Hotel, 5222 Seawall Blvd., Galveston, TX, 77550.
- 05/22/2020
|
Castle Bisociences Grows Despite Covid19 Damping (NASDAQ:CSTL)
- Castle Biosciences went public in July 2019 at $16.00 per share. The firm provides a variety of diagnostic and predictive testing for skin cancers. CSTL has imp
- 05/21/2020
|
New Data Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-SCC Test Results on Patient Management Decisions
- Castle announced publication of an intended use survey for DecisionDx®-SCC for patients diagnosed with high-risk cutaneous squamous cell carcinoma.
- 05/19/2020
|
New Data Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-SCC Test Results on Patient Management Decisions
- Castle announced publication of an intended use survey for DecisionDx®-SCC for patients diagnosed with high-risk cutaneous squamous cell carcinoma.
- 05/19/2020
|
NYC Healthcare Heroes Expands Deliveries to 5,000 Emergency Medical Services and Disaster Services Workers
- NYC Healthcare Heroes is expanding the program to deliver thousands of bags of food and supplies to over 5,000 EMS and disaster services workers.
- 05/14/2020
|
Castle Biosciences Inc (CSTL) Q1 2020 Earnings Call Transcript
- CSTL earnings call for the period ending March 31, 2020.
- 05/12/2020
|
Global Melanoma Markets, Pipeline, Epidemiology, Competitive Analysis, Drug Sales and Shares (2016-2024) - ResearchAndMarkets.com
|
Castle Biosciences Announces First Quarter 2020 Results
- Castle today announced its financial results for the first quarter ended March 31, 2020.
- 05/11/2020
|
Castle Biosciences Announces First Quarter 2020 Results
- Castle today announced its financial results for the first quarter ended March 31, 2020.
- 05/11/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
Castle Biosciences Announces Publication of a Study Evaluating Incorporation of DecisionDx-SCC into Management of High-Risk Cutaneous Squamous Cell Carcinoma
- Castle announced the publication of a clinical utility model for its cutaneous squamous cell carcinoma (SCC) prognostic test, DecisionDx®-SCC.
- 05/05/2020
|
Castle Biosciences Announces Publication of Validation Study for DecisionDx-SCC, Showing this Test is an Independent Predictor of Metastatic Risk in Squamous Cell Carcinoma
- Castle today announced the publication of development and validation data for DecisionDx®-SCC.
- 04/29/2020
|
Castle Biosciences' Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Castle Biosciences.
- 04/28/2020
|
Castle Biosciences to Release First Quarter 2020 Financial Results and Host Conference Call on Monday, May 11, 2020
- Castle Biosciences announced that it will release its financial results for the first quarter 2020, after the close of market on Monday, May 11, 2020.
- 04/27/2020
|
Stocks To Watch: Big Banks And Vaccine Players In The Spotlight
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 04/11/2020
|
Castle Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference
- Castle is scheduled to present at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2020, at 3:30 p.m. Eastern.
- 04/06/2020
|
Castle Biosciences Appoints Miles Harrison to Board of Directors
- Castle today announced that Miles Harrison has been appointed to the board of directors, effective immediately.
- 04/02/2020
|
Castle Biosciences Announces Publication of a Systematic Review and Meta-Analysis Demonstrating DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic Risk
- Castle announced the publication of a systematic review and meta-analysis in JAAD.
- 04/01/2020
|
Castle Biosciences Posts Results of Collaborative Ocular Oncology Group Survey on the Management of Ocular Oncology Patients During the COVID-19 Pandemic
- Castle Posts Results of Collaborative Ocular Oncology Group Survey on the Management of Ocular Oncology Patients During the COVID-19 Pandemic.
- 03/27/2020
|
Castle Biosciences Announces Publication of Fourth Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations for Patients with Uveal Melanoma
- Castle Announces Publication of Fourth Study Demonstrating Significant Impact of DecisionDx-UM on Treatment Plan Recommendations.
- 03/26/2020
|
Head to Head Analysis: Castle Biosciences (NASDAQ:CSTL) and Guardant Health (NASDAQ:GH)
- Castle Biosciences (NASDAQ:CSTL) and Guardant Health (NASDAQ:GH) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations. Earnings and Valuation This table compares Castle Biosciences and Guardant Health’s top-line revenue, earnings per share […]
- 03/22/2020
|
Critical Contrast: Castle Biosciences (NASDAQ:CSTL) versus Guardant Health (NASDAQ:GH)
- Castle Biosciences (NASDAQ:CSTL) and Guardant Health (NASDAQ:GH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability. Profitability This table compares Castle Biosciences and Guardant Health’s net margins, return on equity and return […]
- 03/20/2020
|
Castle Biosciences Announces Fourth Quarter and Full-Year 2019 Results
- Castle announced its financial results for the fourth quarter and twelve months ended December 31, 2019.
- 03/10/2020
|
Castle Biosciences Inc to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / March 10, 2020 / Castle Biosciences Inc (NASDAQ:CSTL) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 10, 2020 at 4:30 ...
- 03/10/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 9.)
Arcutis...
- 03/10/2020
|
The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT)(announced a partnership with Duke-NUS
- 03/05/2020
|
Castle Biosciences Announces Issuance of First U.S. Patent Covering DecisionDx-Melanoma
- Castle was issued its first U.S. patent related to DecisionDx-Melanoma.
- 03/05/2020
|
Netflix And Dow Heavyweights Into The Earnings Confessional
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 01/18/2020
|
Houston-area biotech co. to hire, double office space after $73.6M IPO
- Friendswood-based Castle Biosciences Inc. (Nasdaq: CSTL) has growth in mind after closing a multimillion-dollar initial public offering in 2019. Derek Maetzold, founder, president and CEO of Castle Biosciences, told the Houston Business Journal that the company will more than double its current office space when Castle moves later this year. Castle will occupy 21,760 square feet at 505 S. Friendswood Drive — a new building a little over half a mile away from the company's current digs at 820 S. Friendswood — by late in the second quarter or early Q3, Maetzold said.
- 01/14/2020
|
Does Castle Biosciences (NASDAQ:CSTL) Have A Healthy Balance Sheet?
- Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- 12/24/2019
|
We reveal 4 reasons your sun cream might not be working, causing you to burn
- IT’S summer in Britain and with the heatwave comes the inevitable rainbow of sunburn. With health bods ramming home the importance of sun cream there really is no excuse. Or is there? We all …
- 06/23/2017
|
Skin Analytics Seeks Funds on Crowdcube to Battle Melanoma Using Smartphone App & Attachable Camera
- Hoping to put an end to mortality rate for Melanoma, Skin Analytics has launched an equity crowdfunding campaign on Crowdcube to raise £450,000 for its new ear
- 10/15/2015
|
Castle Biosciences Closes $11.7M Tranche of $20M Series F Financing
- Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced it has closed the first tranche of a $20 mi
- 07/27/2015
|